SANGAMO THERAPEUTICS : ANNOUNCES STRATEGIC UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS - Form 8-K
Dosing of patients in Phase 3 AFFINE trial to support primary analysis complete; pivotal data read-out expected in mid-2024; BLA and MAA submissions anticipated in second half of 2024. ... | April 26, 2023